Efficacy and Safety of Dabigatran Dual Therapy vs Warfarin Triple Therapy in Atrial Fibrillation After PCI in Relation to Time in Therapeutic Range: A Subgroup Analysis From the RE-DUAL PCI Trial.

被引：0

作者：

Lip, Gregory Y. H. ^{[1
]}

Bhatt, Deepak L. ^{[2
]}

Hohnloser, Stefan H. ^{[3
]}

Kimura, Takeshi ^{[4
]}

Meide, Corinna ^{[5
]}

Nordaby, Matias ^{[6
]}

Oldgren, Jonas ^{[7
,8
]}

Steg, Philippe G. ^{[9
]}

ten Berg, Jurrien M. ^{[10
]}

Cannon, Christopher ^{[11
]}

机构：

[1] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England

[2] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA

[3] Goethe Univ Frankfurt, Div Cardiol, Dept Med, Frankfurt, Germany

[4] Kyoto Univ, Dept Cardiovasc Med, Kyoto, Japan

[5] HMS Analyt Software GmbH, Analyt Software, Weimar, Lahn, Germany

[6] Boehringer Ingelheim Int GmbH, TA CardioMetab, Ingelheim, Germany

[7] Uppsala Univ, Uppsala Clin Rsch Ctr, Uppsala, Sweden

[8] Uppsala Univ, Dept Med Sci, Uppsala, Sweden

[9] Hop Bichat Claude Bernard, AP HP, Dept Cardiol, Paris, France

[10] St Antonius Hosp, Cardiol, Nieuwegein, Netherlands

[11] Brigham & Womens Hosp, Test, 75 Francis St, Boston, MA 02115 USA

来源：

CIRCULATION | 2018年 / 138卷

关键词：

Antithrombotic therapy; Atrial fibrillation; Coronary artery disease; Dabigatran; Percutaneous coronary intervention (PCI);

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A11383

引用

页数：3

共 50 条

[31] DOES RENAL FUNCTION INFLUENCE THE BENEFIT OF DUAL ANTITHROMBOTIC THERAPY WITH DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? RESULTS FROM RE-DUAL PCI
Hohnloser, Stefan
Steg, Philippe
Oldgren, Jonas
Nickenig, Georg
Kiss, Robert Gabor
Ongen, Zeki
Estrada, Jose Navarro
Ophuis, Ton Oude
Lip, Gregory
Nordaby, Matias
Kleine, Eva
Ten Berg, Jurrien
Bhatt, Deepak
Cannon, Christopher
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 314 - 314
[32] Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI
Hohnloser, Stefan H.
Steg, Philippe Gabriel
Oldgren, Jonas
Nickenig, Georg
Kiss, Robert G.
Ongen, Zeki
Navarro Estrada, Jose L.
Ophuis, Ton Oude
Lip, Gregory Y. H.
Nordaby, Matias
Kleine, Eva
ten Berg, Jurrien M.
Bhatt, Deepak L.
Cannon, Christopher P.
JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (16) : 1553 - 1561
[33] Evaluation of Antithrombotic Strategies Before and After the First Month of Therapy: Landmark Analysis of the RE-DUAL PCI Trial
Bhatt, Deepak
Steg, Philippe Gabriel
Oldgren, Jonas
Maeng, Michael
Zeymer, Uwe
Halvorsen, Sigrun
Hohnloser, Stefan
Lip, Gregory
Kimura, Takeshi
Nordaby, Matias
Corinna, Miede
Ten Berg, Jurrien
Cannon, Christopher
Peterson, Benjamin
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (17) : B24 - B25
[34] Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
Chi, Gerald
Kerneis, Mathieu
Kalayci, Arzu
Liu, Yuyin
Mehran, Roxana
Bode, Christoph
Halperin, Jonathan L.
Verheugt, Freek W. A.
Wildgoose, Peter
van Eickels, Martin
Lip, Gregory Y. H.
Cohen, Marc
Peterson, Eric D.
Fox, Keith A. A.
Gibson, C. Michael
AMERICAN HEART JOURNAL, 2018, 203 : 17 - 24
[35] A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial
Zwart, Bastiaan
Bor, Willem Lambertus
de Veer, Anne Johanna Wilhelmina Maria
Mahmoodi, Bakhtawar Khan
Kelder, Johannes Christiaan
Lip, Gregory Y. H.
Bhatt, Deepak L.
Cannon, Christopher P.
ten Berg, Jurrien Maria
EUROINTERVENTION, 2022, 18 (04) : E292 - +
[36] What is the significance, if any, of the increased incidence of stent thrombosis with dual therapy of dabigatran 110 mg twice daily and clopidogrel in the RE-DUAL PCI trial?
Rubboli, Andrea
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018, 50 : E27 - E28
[37] Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI
De Caterina, Raffaele
Procopio, Antonio
Lopez Sendon, Jose-Luis
Raev, Dimitar
Mehta, Shamir R.
Opolski, Grzegorz
Oldgren, Jonas
Steg, Philippe Gabriel
Hohnloser, Stefan H.
Lip, Gregory Y. H.
Kimura, Takeshi
Kleine, Eva
ten Berg, Jurrien M.
Bhatt, Deepak L.
Miede, Corinna
Nordaby, Matias
Cannon, Christopher P.
AMERICAN JOURNAL OF MEDICINE, 2020, 133 (11): : 1302 - 1312
[38] Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis
Altoukhi, Renad M.
Alshouimi, Reema A.
Al Rammah, Shahad M.
Alzahrani, Mohammed Y.
Almutairi, Abdulaali R.
Alshehri, Abdulmajeed M.
Alfayez, Osamah M.
Al Yami, Majed S.
Almohammed, Omar A.
BMJ OPEN, 2020, 10 (09):
[39] Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Duerschmied, D.
Brachmann, J.
Darius, H.
Frey, N.
Katus, H. A.
Rottbauer, W.
Schaefer, A.
Thiele, H.
Bode, C.
Zeymer, Uwe
CLINICAL RESEARCH IN CARDIOLOGY, 2018, 107 (07) : 533 - 538
[40] Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis
Hijazi, Ziad
Hohnloser, Stefan H.
Oldgren, Jonas
Andersson, Ulrika
Connolly, Stuart J.
Eikelboom, John W.
Ezekowitz, Michael D.
Reilly, Paul A.
Yusuf, Salim
Wallentin, Lars
AMERICAN HEART JOURNAL, 2018, 198 : 169 - 177

← 1 2 3 4 5 →